Related to Otsuka Earmarks $12M for Continued Cannabinoid Research Partnership with GW Pharmaceuticals

• Protein Kinase Inhibitors for CNS Diseases at the Research and Discovery Phase
  One company has a clinical candidate, but focus for now is to understand kinase involvement in neurodegenerative pathways.
  
• Companies with Cancer Therapeutic Candidates Ramp Up Companion Diagnostic Efforts
  As regulatory framework gets fine-tuned, firms realize the importance of having a biomarker strategy.
  
• Does Clinical Success Mean Commercial Success for Cancer Vaccines?
  Getting insurers to pay for immunotherapies and keeping doctors more informed are key to market growth.
  
• Vaccine Isotype Seems to Affect Clinical Outcome in Blood Cancer Trials
  New results presented at ASH will impact production of autologous immunotherapies.
  
• Avastin Label Changes Reignites Debate: Is OS or PFS the Better Regulatory Endpoint?
  A recent panel discussion set the stage for defining standards for drug approval as separate from those for treatment decisions.
  
• How Provenge Laid the Groundwork for Developing and Regulating Cancer Vaccines
  FDA’s recently issued guidelines pull from more than 20 years of research and clinical experience.
  
• Immune Response Markers for Cancer Vaccines Paint a Clearer Picture
  In trying to understand what constitutes an effective immune response, researchers find it’s all about T cells.
  
• Stakeholders Share Data to Design Better Trials for Neurodegenerative Diseases
  The Coalition Against Major Diseases is pooling clinical data to build disease and drug models.
  
• Leveraging the Cancer Transcriptome for New Drug Targets
  New analytical tools are advancing research efforts.
  
• Why Biomarker Discovery Is Hard
  Differentiating which markers are in the driver’s seat and which are along for the ride is key.
  
• Harvard Professor Rides Genomics' Third Wave
  New Firm Aims to Advance Personalized Medicine through Precision Diagnostics
  
• Will Less SOX2 Lead to Brain Cancer Getting Cold Feet?
  PLK1 level is elevated in glioblastoma multiforme, and its inhibition restricts the growth of brain cancer cells.
  
• Clinical Application of miRNAs Remains a Ways Off
  When and if its time comes, prognostic tests will likely be first.
  
• A SPA for PMTs
  Researchers propose a SPA strategy that can be successfully implemented to identify novel and specific inhibitors of PMTs.
  
• Leveraging Synthetic Lethality for Cancer Therapeutics
  Researchers investigate a class of therapeutics that could short-circuit cancer cells at the molecular level.
  
• Oncogene Addiction: Real or Not?
  Emerging documentation is starting to address that question and increase understanding of process.
  
• Potholes Threaten Medical Marijuana Progress
  Regulatory and political climate in U.S. right now doesn’t favor increasing patient access.
  
• End-Running Cancer Resistance to Targeted Therapies
  Overcoming resistance may require an assault on multiple fronts.
  
• A Cyber War on Cancer
  New strategies are hoping to put an end to the war that Richard Nixon declared four decades ago.
  
• Chemotherapy for the 21st Century
  After a century of using body surface area, oncologists are warming to maximum-tolerated exposure for determining cancer drug dosages.